A Zynerba Pharmaceuticals Inc. investor sued it in Delaware on Wednesday, seeking company records to probe claims that it hid a sky-high incidence of side effects plaguing clinical trials of a treatment for autism-like disorders using cannabidiol, the main non-psychoactive compound in cannabis.
The lawsuit, filed in Delaware Chancery Court, stems from reports of “adverse events” in 96% of trial subjects taking the sole drug candidate in Zynerba’s product pipeline, Zygel, a CBD-based topical gel being tested in patients with autism and three other “progressive neuropsychiatric disorders.”
A majority of the adverse events appear to have been related to Zygel, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.